Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Nov 2026 → Feb 2027
See other at-risk trials from Alliance Foundation Trials, LLC.

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Primary and study completion pushed from Nov 2026 to Feb 2027
    • Eligibility criteria expanded, about 111 words
  3. 2 versions Re-verified since Apr 2, 2026, no change to tracked fieldsv20-v21
  4. Primary completion date: Aug 2025 to Nov 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Oct 2027 to Nov 2026
    • Site details revised at 15 of 15 sites
    v19
  5. Site details revised at 1 of 15 sitesv18
Show 16 earlier versionsHide 16 earlier versions
  1. Study sites: 14 to 15v17
  2. Study sites: 12 to 14v16
  3. Study sites: 7 to 12v15
  4. Site contacts updated at 1 of 7 sitesv14
  5. Study sites: 5 to 7
    • Eligibility criteria expanded, about 3 words
    v13
  6. Re-verified, no change to tracked fieldsv12
  7. Eligibility criteria expanded, about 15 wordsv11
  8. Study sites: 4 to 5v10
  9. Study sites: 3 to 4
    • Eligibility criteria expanded, about 32 words
    v9
  10. Site details revised at 1 of 3 sitesv8
  11. Re-verified, no change to tracked fieldsv7
  12. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 3
    • Start date changed from estimate of Dec 2023 to Dec 7, 2023
    v6
  13. Start date: Oct 2023 to Dec 2023v5
  14. Eligibility criteria expanded, about 28 wordsv4
  15. Start date: Jul 2023 to Oct 2023
    • Primary completion date: Jun 2025 to Aug 2025
    • Study completion date: Jul 2027 to Oct 2027
    v3
  16. Study title shortened, about 9 wordsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Trial Details
NCT Number NCT05798663
Lead Sponsor Alliance Foundation Trials, LLC.
Collaborators: Genentech, Inc.
Conditions
(from sponsor)		 NSCLC
Enrollment 178 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov